David S. Hong, MD
M.D. Anderson Cancer Center
11
10
7
N/A
0
13
Research Impact
N/A
Research impact score
0
Total publications
0
Published trial results
0
Total citations
Drug Portfolio
+12 more interventions
Analytics
Trial Phases
Trial Status
Role Distribution
Activity Timeline
Clinical Trials (11)
Showing 10 of 11 trials
Research Network
Collaboration Network
Research Areas & Affiliations
Therapeutic Areas
Affiliations
Similar Key Opinion Leaders
Discover other key opinion leaders with similar research profiles, therapeutic areas, and collaboration networks.
Steven A Rosenberg, M.D.
National Cancer Institute (NCI)
Shared therapeutic areas:
lin shen
Peking University Cancer Hospital & Institute
Shared therapeutic areas:
E-mail: ClinicalTrials@ ImClone.com
Eli Lilly and Company
Shared therapeutic areas:
Worked with same sponsors:
Lin Shen, MD
Peking University Cancer Hospital & Institute
Shared therapeutic areas:
Norman Wolmark, MD
NSABP Foundation Inc
Shared therapeutic areas:
Worked with same sponsors:
Sabine Hazan, MD
ProgenaBiome
Shared therapeutic areas:
Ajay Goel, PhD
City of Hope Medical Center
Shared therapeutic areas:
Steven A. Rosenberg, MD, PhD
NCI - Surgery Branch
Shared therapeutic areas:
Worked with same sponsors:
Zhenfeng Zhang, MD, PhD
Second Affiliated Hospital of Guangzhou Medical University
Shared therapeutic areas:
Mark Levine, MD
Ontario Clinical Oncology Group (OCOG)
Shared therapeutic areas:
Worked with same sponsors:
Publications (0)
No publications found for this investigator.
Clinical Trials (11)
Showing 11 of 11 trials
Phase I Trial of Adagrasib (MRTX849) in Combination With Cetuximab and Irinotecan in Patients With Colorectal Cancer
Phase II Study of Ilorasertib (ABT348) in Patients With CDKN2A Deficient Solid Tumors
Ipilimumab (Immunotherapy) and MGN1703 (TLR Agonist) in Patients With Advanced Solid Malignancies
Nab-paclitaxel, Gemcitabine, and Bevacizumab in Advanced Malignancies
Gemcitabine and Dasatinib in Advanced Solid Tumors
RTA 402 in Advanced Solid Tumors or Lymphoid Malignancies
Pazopanib, Lapatinib or Trastuzumab in Subjects With Solid Tumors
Lenvatinib and Capecitabine in Patients With Advanced Malignancies
All 11 trials loaded